Indeed, to counteract the antitumor activity of CTX, tumor cells express TGF-β, which inhibits the expression of cytotoxic effector molecules in immune cells (Apo2L/TRAIL, CD95L/FasL, granzyme B, and IFN-γ) and suppresses their ability to induce cetuximab-mediated ADCC (97). This evidence concerns the gene TGFB1 and neoplasm.